Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 539-544

  Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Ikenaka, Yasuhide ^a   Kaji, Kosuke ^a   Aihara, Yosuke ^a   Douhara, Akitoshi ^a   Yamao, Junichi ^a   Toyohara, Masahisa ^a   Mitoro, Akira ^a   Sawai, Masayoshi ^a   Yoshida, Motoyuki ^a   Morioka, Chie ^a   Fujimoto, Masao ^a   Uemura, Masahito ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Branched chain amino acid; Insulin resistance; Liver fibrosis

Indexed keywords

ALBUMIN; BRANCHED CHAIN AMINO ACID; LIVACT; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE;

AMINO ACIDS, BRANCHED-CHAIN; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COLLAGEN TYPE IV; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYALURONIC ACID; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84855645607     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.676     Document Type: Article

References (41)

1. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
2. Fallowfield J and Hayes P: Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? Clin Med 11: 179-183, 2011.
3. Fallowfield JA: Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: G709-G715, 2011.
4. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol 38 (Suppl 1): 38-53, 2003.
5. Povero D, Busletta C, Novo E, et al: Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25: 1075-1091, 2010.
6. Poelstra K and Schuppan D: Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 55: 726-728, 2011.
7. Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y and Fukui H: Impact of renin-angiotensin system in hepatocellular carcinoma. Curr Cancer Drug Targets 11: 431-441, 2011.
8. Kahn CR: Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism 27: 1893-1902, 1978.
9. Shintani Y, Fujie H, Miyoshi H, et al: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848, 2004. (Pubitemid 38298332)
10. Hui JM, Sud A, Farrell GC, et al: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125: 1695-1704, 2003. (Pubitemid 37500434)
11. Petrides AS, Vogt C, Schulze-Berge D, Matthews D and Strohmeyer G: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19: 616-627, 1994. (Pubitemid 24066891)
12. Petit JM, Bour JB, Galland-Jos C, et al: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35: 279-283, 2001. (Pubitemid 32803485)
13. Bugianesi E, McCullough AJ and Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42: 987-1000, 2005. (Pubitemid 43112663)
14. Sugimoto R, Enjoji M, Kohjima M, et al: High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 25: 1018-1026, 2005. (Pubitemid 41404025)
15. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al: Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 29: 1743-1751, 1999. (Pubitemid 29247048)
16. Kaji K, Yoshiji H, Kitade M, et al: Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 22: 801-808, 2008.
17. Marchesini G, Bianchi G, Merli M, et al: Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124: 1792.1801, 2003.
18. Muto Y, Sato S, Watanabe A, et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3: 705-713, 2005. (Pubitemid 40984733)
19. Muto Y, Sato S, Watanabe A, et al: Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35: 204-214, 2006.
20. Nishitani S, Ijichi C, Takehana K, Fujitani S and Sonaka I: Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem Biophys Res Commun 313: 387-389, 2004. (Pubitemid 37543597)
21. Nishitani S, Takehana K, Fujitani S and Sonaka I: Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 288: G1292.G1300, 2005.
22. Iwasa J, Shimizu M, Shiraki M, et al: Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 101: 460-467, 2010.
23. Kawaguchi T, Nagao Y, Matsuoka H, Ide T and Sata M: Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 22: 105-112, 2008.
24. Helmy A, Jalan R, Newby DE, Hayes PC and Webb DJ: Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 118: 565-572, 2000. (Pubitemid 30140855)
25. Bataller R, Gines P, Nicolas JM, et al: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000. (Pubitemid 30346992)
26. Yoshiji H, Kuriyama S, Yoshii J, et al: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001. (Pubitemid 32927999)
27. Yoshiji H, Kuriyama S and Fukui H: Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-356, 2002.
28. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R and Serfaty L: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54: 1003-1008, 2005. (Pubitemid 40873917)
29. Yoshiji H, Kuriyama S, Noguchi R, et al: Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver Int 25: 153-161, 2005. (Pubitemid 40298258)
30. Befeler AS and Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619, 2002. (Pubitemid 34533556)
31. Okita K, Sakaida I and Hino K: Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62 (Suppl 1): 24-28, 2002. (Pubitemid 34702016)
32. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K and Okita K: Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 28: 1247-1252, 1998. (Pubitemid 28493834)
33. Yoshiji H, Noguchi R, Ikenaka Y, et al: Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cummulative recurrence of hepatocellular carcinoma: A randomized control trail. Oncol Rep 26: 1547-1553, 2011.
34. Yoshiji H, Yoshii J, Ikenaka Y, et al: Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 20: 1227-1231, 2002.
35. Rimola A, Londono MC, Guevara G, et al: Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 78: 686-691, 2004. (Pubitemid 39244729)
36. Yoshiji H, Noguchi R, Ikenaka Y, et al: Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development. Int J Mol Med 28: 81-88, 2011.
37. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
38. Kalluri R and Sukhatme VP: Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 9: 413-418, 2000. (Pubitemid 30451697)
39. Yoshiji H, Kuriyama S, Yoshii J, et al: Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347-1354, 2003. (Pubitemid 37026470)
40. Ankoma-Sey V, Wang Y and Dai Z: Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31: 141-148, 2000. (Pubitemid 30033700)
41. Yoshiji H, Noguchi R, Kaji K, et al: Attenuation of insulin-resistance- based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 45: 443-450, 2010.